Clinical Trial Update: Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for tazemetostat as a single agent and in combination in B-cell lymphomas and solid tumors completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mediastinal Large B-cell Lymphoma
• Solid Tumors
• Transformed Follicular Lymphoma

Drugs mentioned

• Tazemetostat (tazemetostat)

Snippet

Sponsor: Epizyme, Inc. | Conditions: B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-08-04